# Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Source: https://onco.cc/trials/nct06769126/  
OnCo record `nct06769126` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06769126 as recruiting, last updated 2026-03-30. Enrolment is 900 planned participants, an estimate. Interventions: Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy. Primary measures include Screen success rate (Screening); Progression-free survival (PFS) (Cohort A). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06769126
- Phase: 2
- Setting: PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Sponsor: SWOG Cancer Research Network

## Sources

- ClinicalTrials.gov NCT06769126: https://clinicaltrials.gov/study/NCT06769126

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct06769126.json